Premier Alternatives

Zag Bio

Drug Delivery · Cambridge, MA · Founded 2022 · Privately Held (backing)

Operator of a therapeutic platform intended to offer precise medicines for immune-mediated diseases. Zag Bio is based in Cambridge, MA and was founded in 2022. Its last reported valuation was $25 million in Jul 2023. It has raised $102 million across 1 recorded round; the latest was an $80 million Series A in Oct 2025.

Last reported valuation
$25.0M
Oct 2026
Priced at
—
Total raised
$102.0M
Last round
Early Stage VC (Series A)
Oct 2025

Zag Bio key facts

as of Oct 2026
  • Operator of a therapeutic platform intended to offer precise medicines for immune-mediated diseases.
  • Zag Bio is valued at approximately $25.0M as of Oct 2026 (last reported valuation).
  • It has raised $102.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($80.0M) in Oct 2025.
  • Notable investors include Gaingels, Pear (California), Alexandria Venture Investments, The Engine, Exitfund — 17 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$25.0M

Zag Bio's last reported valuation, Jul 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Zag Bio with a free account
  • ·The complete investor list: 17 names
  • ·Watch Zag Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Zag Bio funding rounds

1 rounds
Oct 2025Early Stage VC (Series A)$80.0M▮
Full funding history →

Zag Bio valuation

Zag Bio's last reported valuation was $25 million in Jul 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has Zag Bio raised?

Zag Bio has raised $102 million in total; 1 of its rounds is on record. The largest on record was an $80 million Series A in Oct 2025.

Zag Bio investors

17 investors are on record for Zag Bio, including Gaingels, Pear (California), Alexandria Venture Investments and The Engine. By type, the record holds 7 venture capital firms. The Series A in Oct 2025 drew 15 investors.

Comparable companies

Comparable drug delivery names by valuation on PrivateMarketView: Terrestrial Bio ($96.1 million) and Calla Lily Clinical Care ($14.4 million).

About Zag Bio

Operator of a therapeutic platform intended to offer precise medicines for immune-mediated diseases. The company's platform specializes in discovering and developing therapies targeted directly to the thymus, to generate central immune tolerance, enabling professionals to transform the treatment of immune-mediated diseases.

Industry
Drug Delivery
Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2022
Employees
14
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.